Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
EXAS 
EXACT Sciences Corporation (EXAS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/08/2025: EXAS (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
26 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $103.67
1 Year Target Price $103.67
| 17 | Strong Buy |
| 6 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 41.6% | Avg. Invested days 43 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/08/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 19.21B USD | Price to earnings Ratio - | 1Y Target Price 103.67 |
Price to earnings Ratio - | 1Y Target Price 103.67 | ||
Volume (30-day avg) 26 | Beta 1.42 | 52 Weeks Range 38.81 - 101.87 | Updated Date 12/9/2025 |
52 Weeks Range 38.81 - 101.87 | Updated Date 12/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.35 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -32.01% | Operating Margin (TTM) -0.12% |
Management Effectiveness
Return on Assets (TTM) -1.09% | Return on Equity (TTM) -34.54% |
Valuation
Trailing PE - | Forward PE 185.19 | Enterprise Value 20677036893 | Price to Sales(TTM) 6.23 |
Enterprise Value 20677036893 | Price to Sales(TTM) 6.23 | ||
Enterprise Value to Revenue 6.71 | Enterprise Value to EBITDA 215.11 | Shares Outstanding 189765827 | Shares Floating 186860384 |
Shares Outstanding 189765827 | Shares Floating 186860384 | ||
Percent Insiders 0.9 | Percent Institutions 95.29 |
Upturn AI SWOT
EXACT Sciences Corporation
Company Overview
History and Background
EXACT Sciences Corporation was founded in 1999 with the initial goal of developing non-invasive diagnostic tests for cancer. A significant milestone was the development and launch of the Cologuardu00ae test, a groundbreaking stool-based DNA test for colorectal cancer screening, in 2014. This product marked a pivotal shift, positioning the company as a leader in precision diagnostics. Over the years, EXACT Sciences has expanded its portfolio through internal development and strategic acquisitions, broadening its focus beyond colorectal cancer to include other oncology areas and infectious diseases.
Core Business Areas
- Oncology Diagnostics: Developing and commercializing innovative diagnostic tests for cancer detection, screening, and monitoring. This includes multi-cancer early detection tests and companion diagnostics.
- Infectious Disease Diagnostics: Offering diagnostic solutions for infectious diseases, including tests for respiratory illnesses and other pathogens.
- Data and Analytics: Leveraging genomic data and advanced analytics to provide insights that support personalized medicine and drug development.
Leadership and Structure
EXACT Sciences Corporation is led by a seasoned management team with expertise in diagnostics, biotechnology, and commercialization. The organizational structure is designed to support its research and development, manufacturing, sales, and marketing operations across its various product lines. Key leadership roles include CEO, CFO, Chief Medical Officer, and heads of R&D and commercial functions.
Top Products and Market Share
Key Offerings
- Cologuardu00ae: A stool-based DNA test for colorectal cancer screening. It is a leading non-invasive screening option, commanding a significant share of the colorectal cancer screening market. Key competitors include traditional colonoscopy and other stool-based tests like FIT (fecal immunochemical test).
- Cancer Interceptu2122: A portfolio of tests aimed at early cancer detection and monitoring, including tests for multiple cancers. This is a rapidly evolving area with significant competition from established diagnostic companies and emerging biotech firms.
- Germinalu2122: Tests for infectious diseases, providing rapid and accurate diagnosis. This segment competes with numerous diagnostic companies offering solutions for various pathogens.
Market Dynamics
Industry Overview
The diagnostics industry is characterized by rapid technological advancements, increasing demand for precision medicine, early disease detection, and personalized healthcare solutions. The oncology diagnostics market, in particular, is growing due to an aging population, rising cancer incidence, and advancements in genomic sequencing and molecular diagnostics.
Positioning
EXACT Sciences is a leader in non-invasive cancer screening, particularly with its flagship Cologuardu00ae product. Its strengths lie in its innovative technology, strong commercial execution, and expanding product pipeline. The company is well-positioned to capitalize on the growing demand for early cancer detection and precision diagnostics.
Total Addressable Market (TAM)
The total addressable market for cancer diagnostics and screening is in the hundreds of billions of dollars globally, encompassing screening, early detection, diagnosis, treatment selection, and monitoring. EXACT Sciences is aggressively pursuing a significant portion of this TAM through its expanding portfolio of tests, aiming to become a comprehensive diagnostics provider.
Upturn SWOT Analysis
Strengths
- Pioneering non-invasive diagnostic tests (Cologuardu00ae)
- Strong brand recognition and market presence in colorectal cancer screening
- Robust R&D pipeline for early cancer detection and multi-cancer tests
- Established sales and marketing infrastructure
- Strategic partnerships and collaborations
Weaknesses
- High R&D investment and associated costs
- Dependence on reimbursement from payers for test adoption
- Competition from established diagnostic players and novel technologies
- Potential for regulatory challenges and market access hurdles
Opportunities
- Expansion into new cancer types and indications for early detection
- Growth in the multi-cancer early detection market
- Leveraging data analytics for personalized medicine
- International market expansion
- Strategic acquisitions to broaden capabilities
Threats
- Intensifying competition from new entrants and established players
- Changes in healthcare policy and reimbursement landscapes
- Technological obsolescence as new diagnostic methods emerge
- Potential for negative clinical trial outcomes or regulatory setbacks
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- Guardant Health, Inc. (GH)
- Roche Holding AG (RHHBY)
- Thermo Fisher Scientific Inc. (TMO)
- Abbott Laboratories (ABT)
- Illumina, Inc. (ILMN)
Competitive Landscape
EXACT Sciences benefits from its first-mover advantage and strong brand recognition in colorectal cancer screening. Its focus on non-invasive diagnostics is a key differentiator. However, it faces intense competition from large, diversified healthcare companies and agile biotech startups, many of which have significant R&D resources and established market access.
Major Acquisitions
Genomic Health
- Year: 2019
- Acquisition Price (USD millions): 2700
- Strategic Rationale: Acquired Genomic Health to expand its oncology portfolio into genomic profiling and personalized medicine, particularly for cancer treatment selection and monitoring.
BaseClear B.V.
- Year: 2021
- Acquisition Price (USD millions): 36
- Strategic Rationale: Acquired BaseClear B.V. to strengthen its capabilities in microbiome analysis and microbial genomics, supporting the development of novel diagnostics.
Growth Trajectory and Initiatives
Historical Growth: EXACT Sciences has demonstrated strong historical revenue growth, propelled by the successful launch and market penetration of Cologuardu00ae and the expansion of its product offerings. The company has consistently invested in its commercial infrastructure to support this growth.
Future Projections: Analysts project continued revenue growth for EXACT Sciences, driven by the expansion of its oncology portfolio, including multi-cancer early detection tests, and increasing adoption of its existing products. Profitability is expected to improve as sales scale and R&D efficiencies are realized.
Recent Initiatives: Recent initiatives include the expansion of its multi-cancer early detection platform, strategic acquisitions to enhance its diagnostic capabilities, and increased investment in its commercial sales force to drive broader test adoption.
Summary
EXACT Sciences Corporation is a strong player in the rapidly growing diagnostics market, particularly in oncology. Its innovative Cologuardu00ae test has established a significant market presence, and its expanding pipeline of early cancer detection technologies offers substantial growth potential. Key strengths include its R&D capabilities and commercial execution. However, the company must navigate intense competition, significant R&D investment, and evolving reimbursement landscapes to maintain its growth trajectory and achieve profitability.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations Filings (SEC)
- Financial News and Analysis Websites
- Industry Market Research Reports
Disclaimers:
This analysis is based on publicly available information and is intended for informational purposes only. It does not constitute financial advice. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About EXACT Sciences Corporation
Exchange NASDAQ | Headquaters Madison, WI, United States | ||
IPO Launch date 2001-02-01 | Chairman of the Board & CEO Mr. Kevin T. Conroy J.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 6900 | Website https://www.exactsciences.com |
Full time employees 6900 | Website https://www.exactsciences.com | ||
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.